Body Mass Index and Response to Asthma Therapy: Fluticasone Propionate/Salmeterol versus Montelukast
Authors:
- 25 January 2010
- journal article
- research article
- Published by Taylor & Francis in Journal of Asthma
- Vol. 47 (1) , 76-82
Abstract
We studied the relationship between body mass index (BMI) on responses to asthma therapy using a retrospective analysis of four previously reported clinical trials. Fluticasone propionate (FP)/salmeterol via Diskus 100/50 μg twice daily and montelukast (MON) 10 mg daily were compared. BMI was classified as underweight (less than 20 kg/m2), normal (20–24.9 kg/m2), overweight (25–29.9 kg/m2), obese-1 (30–34.9 kg/m2), obese-2 (35–39.9 kg/m2), or obese-3 (at least 40 kg/m2). Outcomes assessed included forced expiratory volume in one second (FEV1), asthma symptom score, and albuterol use. FP/salmeterol produced greater improvements compared to MON in each of the asthma outcomes studied over the entire BMI range at the week-12 endpoint, with statistically significant differences noted among normal, overweight, obese-1, and obese-3 subjects. The within-treatment responses to FP/salmeterol across BMI ranges at the week-12 endpoint was statistically significantly greater in normal compared to obese-3 for FEV1 and albuterol use, and in overweight compared to the obese-3 for each outcome studied. The within-treatment comparisons of MON across BMI ranges were significant for albuterol use in normal and underweight compared to obese-3 at the week-12 endpoint. Compared to subjects with normal BMI, the onset to peak FEV1 may require longer treatment exposure in the very obese. Treatment responses to FP/salmeterol were consistently greater compared to MON and persisted at higher BMI.Keywords
This publication has 34 references indexed in Scilit:
- Body mass index and phenotype in subjects with mild-to-moderate persistent asthmaJournal of Allergy and Clinical Immunology, 2009
- Obesity and AsthmaImmunology and Allergy Clinics of North America, 2008
- Airway inflammation in obese and nonobese patients with difficult‐to‐treat asthmaAllergy, 2008
- Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are “Stepped-Down”Journal of Asthma, 2008
- Long-Acting β2-Adrenoceptor Agonists Synergistically Enhance Glucocorticoid-Dependent Transcription in Human Airway Epithelial and Smooth Muscle CellsMolecular Pharmacology, 2008
- Smoking Affects Response to Inhaled Corticosteroids or Leukotriene Receptor Antagonists in AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Overweight, Obesity, and Incident AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Combination Therapy with a Long-Acting β-Agonist and a Leukotriene Antagonist in Moderate AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Nitrogen washout slope in poorly controlled asthmaAllergy, 2005
- Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthmaAnnals of Allergy, Asthma & Immunology, 2002